– AXLA common stock expected to begin trading on a split-adjusted basis on September 19, 2023 – Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company's common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The Nasdaq Global Market. The Company's common stock is expected to commence trading on a split-adjusted basis when the markets open on Septembe

Claims cover methods of treating a subject presenting with fatigue from post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, with Candidate AXA1125 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, particularly fatigue. The patent was issued on August 29, 2023, with anticip

AXA1125 remains the most advanced product to help patients experiencing fatigue post acute COVID-19 The Company continues to pursue a strategic alternative for stakeholders Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced financial results for the second quarter ended June 30, 2023 and provided a business update. "Patients are seeking relief from Long COVID fatigue. Axcella's proprietary composition of amino acids in AXA1125 in Long COVID fatigue is potentially an important step to help people mainta

Long COVID Phase 2b/3 clinical trial may proceed under U.S. Investigational New Drug application MHRA guidance aligns on key measurements for a Long COVID registration trial, including primary endpoint and trial design elements Lancet eClinical Medicine published findings from the Phase 2a clinical trial of AXA1125 in Long COVID Fatigue online on April 14, 2023 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2023 and provided a business update. "Patients are s

Dr. Lucy E.M. Finnigan will present on the Phase 2a clinical trial of AXA1125 in Long COVID Fatigue on April 18 Dr. Finnigan will also report on AXA1125 treatment effects on biomarkers of mitochondrial energetics and vascular endothelial function on April 17 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced two oral presentations of results from the Phase 2a clinical trial of AXA1125 in the treatment of Long COVID Fatigue at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), as a hybrid event

Long COVID Phase 2b/3 study may proceed under U.S. Investigational New Drug application MHRA guidance aligns on key measurements for a Long COVID registration trial, including primary endpoint and trial design elements Axcella presented at Long COVID forum co-sponsored by BIO and Solve M.E. The Company repositioned its strategy to focus on Long COVID Engaged an investment bank to act as a strategic advisor as we explore a range of strategic alternatives to maximize stakeholder value Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, t

Phase 2b/3 study may proceed under U.S. Investigational New Drug application Study design now accepted by U.S. and U.K. regulatory authorities Axcella to present at Long COVID forum co-sponsored by BIO and Solve M.E. Axcella to host a conference call February 16 at 8:00 a.m. ET; To register, click here Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced its Investigational New Drug (IND) application to initiate a phase 2b/3 trial in the U.S. for AXA1125 in the treatment of Long COVID Fatigue has been cleared by the U.S. F

Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that CEO Bill Hinshaw will present a company update at SVB Securities' 2023 Global Biopharma Conference, taking place virtually February 14-16, 2023. Details for Axcella's participation are as follows: Date:   Thursday, February 16, 2023 Time:   11:20 am Eastern Time Webcast:   https://wsw.com/webcast/svb8/axla/1608786 The conference call webcast will be accessible in the Investors & News section on the company's website at www.axcellatx.com. An archive

MHRA guidance aligns on key measurements for a registration trial, including primary endpoint and trial design elements IND for phase 2b/3 trial submitted to the FDA Axcella to host a conference call Tuesday, January 24 at 8:00 a.m. ET; To register, click here Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, announced a regulatory path to registration of AXA1125 in the treatment of Long COVID Fatigue. The company reported that it had received regulatory guidance from The Medicines and Healthcare products Regulatory Agency (MHRA), the U

Move Positions Company to Best Focus on Long COVID Program Axcella Therapeutics (NASDAQ:AXLA), a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announces a repositioning of its strategy to focus on Long COVID and realize value from its platform and current programs. The company has initiated a process to explore a range of strategic alternatives to maximize shareholder value and is working with an investment bank to act as a strategic advisor for this process. As part of this repositioning, and to align with its current capital constraints, the company is announcing a series of organiza